Get the Stockscreener App
66.28
0.87%
0.57
Pre-market:
66.50
0.22
+0.33%
Bio Rad Laboratories Inc stock is traded at $66.28, with a volume of 4.25M.
It is up +0.87% in the last 24 hours and down -18.24% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$65.71
Open:
$65.85
24h Volume:
4.25M
Relative Volume:
2.43
Market Cap:
$12.96B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-17.69
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
-1.53%
1M Performance:
-18.24%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$65.33
$67.30
1-Week Range:
$64.90
$70.00
52-Week Range:
$64.90
$89.49
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bio Rad Laboratories Inc
|
66.28 | 12.96B | 579.96M | -729.89M | -452.02M | -3.7459 |
ABT
Abbott Laboratories
|
101.07 | 174.89B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.51 | 113.22B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
269.75 | 103.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.68 | 64.75B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.73 | 49.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BBIO) Latest News
BIO: Multi-year transformation leverages technology, M&A, and restructuring to drive growth and margin expansion - TradingView
BIO: Multi-year transformation leverages digital PCR leadership and targeted M&A for growth - TradingView
Bio-Rad at bernstein healthcare forum: shift toward profitable growth - Investing.com
Bio-Rad Laboratories, Inc. at Bernstein Insights Healthcare Leaders and Disruptors Transcript - GuruFocus
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher - finance.yahoo.com
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher - Investing.com
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher - quiverquant.com
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring - The Manila Times
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - finance.yahoo.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Challenges in the Medical Devices Sector - DirectorsTalk Interviews
Bio-rad Laboratories Stock Price Forecast. Should You Buy BIO? - StockInvest.us
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - finance.yahoo.com
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues - Yahoo Finance
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Bio-Rad Laboratories Inc. Class A (BIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - manufacturingchemist.com
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Best Practices for qPCR Assay Design and Optimization - the-scientist.com
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - Cambridge Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with a -15.14% Potential Downside - DirectorsTalk Interviews
Bio-Rad Laboratories Inc. Class A (BIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Discipline and Rules-Based Execution in BIO Response - Stock Traders Daily
Bio-Rad Laboratories stock hits 52-week high at 394.22 USD - Investing.com Nigeria
Bio-Rad Laboratories (BIO) Edges Lower to $388.77 as Shares Consolidate Between Key Support and ResistanceWyckoff Upthrust - careplusvn.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Upside Amidst Market Challenges - directorstalkinterviews.com
Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends - Sahm
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
Bio-Rad (BIO) Move: Finishes 0.71% Lower at $373.79 on the Day; Key Range: the Session Ends Within the Reported Technical Boundaries on the DayBlue Chip Entry Points - careplusvn.com
Bio-Rad (BIO) Quarter in Focus: Profit Per Share Clears Its Benchmark for the Current Session - vinanet.vn
Bio-Rad Laboratories Inc (BIO) Shares Surge 3.4% -- What GF Scor - GuruFocus
Bio Rad Laboratories Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):